BRIEF-Tecvayli® Monotherapy Demonstrates Superior Progression-Free And Overall Survival Versus Standard Of Care As Early As First Relapse In Patients With Multiple Myeloma Predominantly Refractory To Anti-Cd38 Therapy And Lenalidomide
Reuters01-15
BRIEF-Tecvayli® Monotherapy Demonstrates Superior Progression-Free And Overall Survival Versus Standard Of Care As Early As First Relapse In Patients With Multiple Myeloma Predominantly Refractory To Anti-Cd38 Therapy And Lenalidomide
TECVAYLI® MONOTHERAPY DEMONSTRATES SUPERIOR PROGRESSION-FREE AND OVERALL SURVIVAL VERSUS STANDARD OF CARE AS EARLY AS FIRST RELAPSE IN PATIENTS WITH MULTIPLE MYELOMA PREDOMINANTLY REFRACTORY TO ANTI-CD38 THERAPY AND LENALIDOMIDE
J&J - 71% REDUCTION IN DISEASE PROGRESSION RISK AND 40% REDUCTION IN DEATH RISK
J&J - TECVAYLI MONOTHERAPY SAFETY PROFILE MANAGEABLE WITH NO NEW CONCERNS
Source text: ID:nPnbBpwsca
Further company coverage: JNJ.N
((Reuters.Briefs@thomsonreuters.com;))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments